Although low-density lipoprotein (LDL)-cholesterol lowering with the statins
reduces the mortality and morbidity associated with coronary artery disease, ...
Jun 30, 2016 ... Without the surrogate endpoint of LDL lowering the approval would be pushed
back ... Esperion also announced that the CVOT, which will be known as ... Given
the modest success of the PCSK9 inhibitors so far does it even ...
Jun 30, 2016 ... Without the surrogate endpoint of LDL lowering, the approval would be pushed
back to 2022 ... Esperion also announced that the cardiovascular outcomes trial,
which will be known as Cholesterol Lowering via Bempedoic Acid, ... Given the
modest success of the PCSK9 inhibitors so far, does it even matter ...
Understanding Cholesterol Lowering. At Esperion, we are leveraging our
experience and understanding of key biological pathways to develop and ...
Jan 10, 2017 ... These treatments, both novel ones and me-toos, are being met with payer ...
scientific director at Discovery USA, predicts payers will continue to ... As a result,
companies lost interest in investing in new approaches to lowering cholesterol. ...
Esperion's bempedoic acid, an oral cholesterol-lowering treatment ...
Apr 18, 2015 ... Statins' cholesterol-lowering ability and a growing global need for cholesterol-
busting ... Targeting cholesterol in this manner is a novel approach, and results
from ... Those clinical trial results could mean that the FDA will give the drug a
green light ... 3: Esperion Therapeutics (NASDAQ:ESPR) -- ETC-1002
Jan 29, 2011 ... The singular focus on treating cholesterol. ... At best this new “super cholesterol”
drug will lower cholesterol numbers .... and pre-diabetes or metabolic syndrome
can be successfully diagnosed and treated. ... For the vast majority of people this
approach is better than simply taking a cholesterol medication.
Good leadership skills are essential to build a successful practice. ... with
elevated atherogenic cholesterol levels and statin intolerance based on safety
and efficacy. ... Attendees will leave with the latest information on novel LDL
lowering ... Managing Inflammation: A Novel Approach for Secondary Prevention
of CVD Risks.
... CBLI) is an innovative biopharmaceutical company developing novel
approaches to activate ... About the Company: Esperion is a pharmaceutical
company focused on ... oral, low-density lipoprotein cholesterol (LDL-C) lowering
therapies for the ... Healthcare data can span across a disparate ecosystem of
employed and ...
Nov 25, 2013 ... It is also interesting that LDL lowering agents, other than statins, have ... /05/
esperions-novel-approach-to-lowering-cholesterol-will-it-be-successful/ .... Pfizer
bought Esperion for a billion $ in order to protect Lipitor's 12 billion ...